Last Updated: November 16, 2026

List of Excipients in Branded Drug OLINVYK

« Back to Dashboard


Company Tradename Ingredient NDC Excipient Potential Generic Entry
Trevena Inc OLINVYK oliceridine 71308-011 HISTIDINE 2032-03-23
Trevena Inc OLINVYK oliceridine 71308-011 MANNITOL 2032-03-23
Trevena Inc OLINVYK oliceridine 71308-011 WATER 2032-03-23
>Company >Tradename >Ingredient >NDC >Excipient >Potential Generic Entry

OLINVYK Excipient Strategy and Commercial Opportunities

Last updated: August 23, 2026

OLINVYK (oliceridine) is a sterile, preservative-free intravenous opioid injection approved by the FDA for the management of acute pain severe enough to require an intravenous opioid analgesic when alternative treatments are inadequate. Its excipient system is commercially conservative: citrate buffering, sodium chloride for tonicity, and water for injection. The main opportunities are not a new excipient composition alone. They are ready-to-administer presentations, container-closure systems, stability improvements, hospital workflow products, and differentiated delivery formats supported by new FDA filings.

What excipients are used in OLINVYK?

The OLINVYK injection formulation contains oliceridine fumarate at an equivalent concentration of 1 mg/mL of oliceridine. The inactive ingredients are:

Component Function Commercial relevance
Citric acid monohydrate Acid component of citrate buffer Controls solution pH and supports chemical stability
Sodium citrate dihydrate Buffer component Maintains formulation pH
Sodium chloride Tonicity agent Supports compatibility with intravenous administration
Water for injection Vehicle Sterile injectable solvent

The product is an aqueous, sterile, single-dose formulation with a reported pH range of approximately 4.0 to 5.0. OLINVYK is supplied in 30 mg/30 mL single-dose containers, including vial and premixed-bag presentations described in product materials.[1]

The formulation excludes preservatives. That is consistent with a high-risk intravenous opioid product intended for hospital use, where preservative exposure and multidose handling create avoidable safety and compatibility concerns.

Why the citrate system matters

The citrate buffer is the central formulation-control element. Oliceridine is administered as the fumarate salt, and the formulation must maintain:

  • Chemical stability during refrigerated and room-temperature storage
  • Acceptable pH for intravenous administration
  • Compatibility with the primary container and administration set
  • Consistent assay and impurity profile over shelf life
  • Low particulate and extractables risk

A citrate-buffered injectable formulation is technically familiar and relatively easy to source. That lowers raw-material barriers for competitors. It also means that the strongest commercial protection is more likely to arise from presentation, packaging, device integration, manufacturing controls, or clinical workflow than from the basic excipient combination.

What excipient strategy does OLINVYK use?

OLINVYK uses a minimal-excipient strategy rather than a complex formulation platform. The commercial advantages are manufacturing simplicity, a limited number of raw materials, and a lower risk of excipient-related tolerability concerns.

Formulation objectives

The excipient architecture appears designed to achieve four objectives:

  1. Maintain a stable acidic aqueous solution.
  2. Provide near-isotonic administration through sodium chloride.
  3. Avoid preservatives in a single-dose injectable product.
  4. Support direct hospital administration without reconstitution.

The formulation does not depend on specialized solubilizers, surfactants, lipids, cyclodextrins, polymers, or lyophilization. This reduces formulation complexity but also limits differentiation based solely on inactive ingredients.

Supply-chain implications

The excipients are commodity or widely available pharmaceutical-grade materials. A commercial competitor would not face the same supply barriers associated with proprietary lipid systems, recombinant proteins, novel polymers, or restricted excipient suppliers.

The more meaningful supply-chain risks are:

  • Qualified sterile manufacturing capacity
  • Citrate raw-material quality and microbial control
  • Container-closure integrity
  • Extractables and leachables from bags, vials, ports, and administration sets
  • Stability of the finished product after dilution or transfer
  • Controlled-substance manufacturing and distribution requirements

For a hospital injectable opioid, the active pharmaceutical ingredient and controlled-substance compliance program are likely to be greater barriers than the excipients.

What formulation opportunities exist for OLINVYK?

The strongest commercial opportunities involve a redesigned presentation rather than a simple excipient substitution.

Ready-to-administer syringe

A prefilled syringe could reduce preparation time, dosing errors, and waste in emergency departments, operating rooms, and postoperative units. A syringe product would require new data on:

  • Drug adsorption to syringe components
  • Silicone oil and tungsten residues
  • Plunger and stopper compatibility
  • Needle-free connector performance
  • In-use stability
  • Dose accuracy at low withdrawal volumes
  • Container-closure integrity

A prefilled syringe could support a premium hospital price if it materially reduces pharmacy preparation and administration steps.

Standardized low-volume doses

OLINVYK is available at a 1 mg/mL concentration. Unit-dose presentations could be optimized for common bolus and infusion requirements, such as 1 mg, 2 mg, or 5 mg doses. Smaller containers could reduce drug wastage and improve automated dispensing cabinet utilization.

The commercial tradeoff is additional inventory complexity. Hospitals may prefer one concentration and one presentation unless the new format demonstrates measurable workflow or safety benefits.

Premixed infusion bags

Premixed bags are a natural extension of the current product because they eliminate pharmacy compounding. A differentiated bag could target:

  • Postoperative continuous infusion
  • Intensive-care-unit analgesia
  • Patient-controlled analgesia systems
  • Standardized electronic medication-library configurations
  • Reduced opioid preparation burden

The key technical issue is stability after connection to infusion equipment. A product sponsor would need compatibility data covering common bags, tubing, ports, filters, and pumps.

Extended in-use stability

A formulation or package that extends in-use stability after opening, dilution, or connection to an infusion set could create a hospital value proposition. Such a claim would require validated stability data under realistic conditions, including temperature excursions, light exposure, agitation, and contact with administration materials.

Alternative buffering or tonicity systems

Potential formulation research could evaluate phosphate, acetate, or other buffering systems, as well as alternative tonicity agents. These changes would not automatically create a superior product. They could introduce new risks involving precipitation, pH drift, osmolality, degradation, or intravenous tolerability.

A citrate-to-phosphate substitution, for example, would require comparative stability and compatibility evidence. It could also create a new formulation patent position if the composition produced an unexpected stability or impurity advantage.

What patents could protect an OLINVYK reformulation?

A simple citrate, sodium chloride, and water formulation is unlikely to provide a broad commercial moat unless the claims include a narrow but valuable combination of concentration, pH, storage condition, container, or use.

Potential claim categories include:

Claim category Example protected subject matter Commercial value
Composition Oliceridine concentration, buffer ratio, pH, osmolality Moderate if linked to unexpected stability
Container Specific vial, syringe, bag, stopper, port, or polymer Moderate to high for a hospital presentation
Stability Defined impurity limits after storage or in-use administration High if difficult to reproduce
Administration Premixed product compatible with a defined infusion system Moderate
Dose form Ready-to-administer syringe or unit-dose container High for workflow differentiation
Method of use Oliceridine for acute pain in a defined clinical population Variable, subject to statutory and litigation limits
Manufacturing Crystallization, sterile filtration, filling, or impurity-control process Moderate where process yields are difficult to match

A formulation patent should connect the excipient choice to a measurable technical result. Claims limited to the use of conventional citrate buffer and sodium chloride may face obviousness challenges if comparable opioid injection formulations establish the same design approach.

When does OLINVYK lose regulatory exclusivity?

OLINVYK was approved by the FDA on August 7, 2020.[2] Oliceridine received designation as a qualified infectious disease product? No. The relevant regulatory exclusivity and patent analysis must be separated from the product’s opioid indication.

The FDA approval was for acute pain requiring an intravenous opioid analgesic when alternative treatments are inadequate. As a small-molecule drug, OLINVYK is subject to an ANDA-based generic pathway, not a biosimilar pathway.

Exclusivity issue OLINVYK implication
New chemical entity exclusivity Generally five years from approval for an eligible new active ingredient
Paragraph IV timing A generic applicant may file a patent challenge during the applicable exclusivity period, but approval timing remains restricted
Pediatric exclusivity A six-month extension applies only if FDA pediatric requirements are completed and granted
QIDP exclusivity Must be confirmed from the approval and product-designation record before being included in a launch forecast
Biosimilar pathway Not applicable because oliceridine is a synthetic small molecule
Orange Book Relevant if FDA-listed patents cover the drug, formulation, or approved methods of use

A commercial forecast should not treat regulatory exclusivity as equivalent to patent protection. Generic entry depends on active patents, listed use claims, settlement terms, court outcomes, and the filing date of the first substantially complete ANDA.

What is the Orange Book and patent status of OLINVYK?

The FDA Orange Book is the controlling source for listed patents and exclusivity codes. OLINVYK’s patent exposure should be evaluated through:

  1. FDA Orange Book listings for OLINVYK and oliceridine fumarate.
  2. FDA approval-letter materials.
  3. USPTO patent assignment and maintenance records.
  4. Federal district court and Federal Circuit litigation records.
  5. ANDA litigation and settlement disclosures.
  6. Trevena’s SEC filings and licensing announcements.

No biosimilar litigation applies. Any generic challenge would proceed through an ANDA and could include Paragraph IV certifications against listed patents.

The key diligence issue is whether listed patents cover only the active ingredient or also the commercial injection, dosing regimen, or method of use. A formulation-specific patent can delay generic entry only if it is listed, enforceable, and relevant to the proposed ANDA product.

Which companies are challenging OLINVYK?

The competitive threat is primarily from established injectable opioids and potential generic oliceridine, not biosimilar developers.

Competitor Active ingredient Typical commercial position
Morphine injection Morphine sulfate Low-cost hospital standard
Hydromorphone injection Hydromorphone hydrochloride High-potency opioid alternative
Fentanyl injection Fentanyl citrate Common perioperative and acute-care product
Remifentanil Remifentanil hydrochloride Short-acting procedural and anesthesia use
Oliceridine generic Oliceridine Direct ANDA competition if approved

OLINVYK’s differentiation is pharmacologic rather than excipient-driven. The product was developed as a G-protein-biased mu-opioid receptor agonist intended to provide analgesia with potentially different respiratory and gastrointestinal effects from conventional opioids. The FDA label still contains class opioid warnings, including respiratory depression, abuse, misuse, addiction, and life-threatening overdose.[1]

Hospitals will compare OLINVYK on total treatment cost, pharmacy workload, respiratory monitoring, nausea and vomiting, ileus, length of stay, and formulary restrictions. A premium excipient or package strategy must show operational value against inexpensive generic morphine, hydromorphone, and fentanyl.

What generic launch risks exist for OLINVYK?

A generic launch could follow several paths:

Scenario 1: Same formulation, same presentation

This is the highest-risk scenario for the branded product. A generic manufacturer could seek approval for an equivalent sterile injection using the same concentration and a comparable excipient profile. The commercial advantage would be price, formulary access, and established hospital distribution.

Scenario 2: Paragraph IV challenge with delayed approval

A generic applicant could challenge listed patents while the branded product retains market protection. The outcome would depend on patent validity, infringement, and any settlement agreement. A first filer could potentially obtain 180-day exclusivity under the ANDA framework, affecting later generic entrants.

Scenario 3: Reformulated or alternative presentation

A competitor could pursue a different container or excipient system through an ANDA or 505(b)(2) pathway, depending on the extent of formulation and clinical differences. A 505(b)(2) product could target a prefilled syringe, alternative concentration, or different administration method while relying partly on existing FDA findings.

Scenario 4: Hospital substitution by conventional opioids

This does not require patent expiry. OLINVYK can lose share before generic entry if hospital systems restrict use because of price, opioid stewardship policies, formulary contracting, or limited evidence of economic benefit.

How strong is the OLINVYK excipient patent opportunity?

The excipient patent opportunity is moderate for the base formulation and stronger for integrated delivery systems.

Stronger opportunities

  • A ready-to-administer syringe with validated long-term stability
  • A premixed infusion bag with extended in-use stability
  • A specific container and closure that controls adsorption or leachables
  • A formulation that reduces degradation impurities without increasing osmolality
  • A stable low-volume unit-dose format that reduces hospital waste
  • A package compatible with automated dispensing and smart-pump systems

Weaker opportunities

  • Replacing one conventional buffer with another without an unexpected result
  • Broad claims to citrate-buffered oliceridine injection
  • Generic use of sodium chloride for tonicity
  • Claims based only on a conventional acidic pH range
  • Minor concentration changes without clinical or stability differentiation

Patent strength will depend on claim breadth, comparative examples, prior-art injectable opioid formulations, enablement, and whether the protected product is commercially important to the ANDA applicant.

What licensing and commercial deals could support OLINVYK?

The most logical licensing targets are companies with:

  • Hospital injectable portfolios
  • Controlled-substance distribution infrastructure
  • Prefilled syringe manufacturing
  • Premixed infusion bag capacity
  • Automated dispensing cabinet integration
  • Acute-care sales teams
  • Global rights outside the United States

Potential deal structures include regional commercialization licenses, co-development of a ready-to-administer presentation, supply agreements for sterile bags or syringes, and royalty-bearing rights to a formulation patent.

A partner would likely require evidence that the product can gain formulary placement against generic opioids. Excipient innovation alone is unlikely to justify a major upfront payment. A stronger transaction case would combine improved hospital workflow, reduced preparation error, a protected package, and clinical or pharmacoeconomic evidence.

What is the FDA regulatory pathway for an OLINVYK reformulation?

A reformulated oliceridine product could require:

  • An FDA supplemental application if the change remains within the approved product framework
  • A 505(b)(2) application for a materially different dosage form, concentration, route, or formulation
  • Updated chemistry, manufacturing, and controls data
  • Comparative stability and impurity data
  • Container-closure integrity testing
  • Extractables and leachables assessment
  • In-use compatibility studies
  • Human factors work for a prefilled syringe or device-linked presentation
  • Controlled-substance security and distribution controls

The regulatory burden increases when the change affects dose delivery, infusion performance, administration devices, or clinical exposure. A new excipient with limited prior intravenous use would require a more extensive safety justification.

Key Takeaways

  • OLINVYK uses a simple preservative-free aqueous formulation based on citrate buffer, sodium chloride, and water for injection.
  • The base excipient combination is commercially reproducible and unlikely to create a strong standalone barrier.
  • The best commercial opportunities are prefilled syringes, unit-dose containers, premixed infusion bags, and extended in-use stability.
  • OLINVYK competes against generic morphine, hydromorphone, fentanyl, and other hospital opioids.
  • Oliceridine is a small molecule, so biosimilar competition does not apply.
  • Generic risk depends on Orange Book patents, Paragraph IV filings, ANDA timing, and any settlement agreements.
  • A successful reformulation strategy must prove lower hospital workload, reduced waste, improved handling, or a clinically meaningful benefit.
  • A formulation patent is strongest when it protects a specific package or stability result rather than conventional citrate buffering alone.

FAQs

Can OLINVYK be reformulated without changing the active ingredient?

Yes. A reformulation could change the buffer, concentration, container, dosage form, or administration presentation. The FDA pathway would depend on the extent of the change and whether the sponsor can rely on existing safety and efficacy findings.

Is OLINVYK preservative-free?

Yes. The labeled formulation uses citrate buffer, sodium chloride, and water for injection and does not identify a preservative.[1]

Could a prefilled OLINVYK syringe receive separate patent protection?

Yes. Patent claims could cover the syringe components, drug concentration, container-closure system, stability profile, dose configuration, or administration method. Patentability would depend on novelty, nonobviousness, enablement, and commercial relevance.

Does OLINVYK have biosimilar competition?

No. Oliceridine is a synthetic small-molecule active ingredient. Potential competitors would generally use the ANDA generic pathway rather than the biosimilar pathway.

What would make an OLINVYK excipient license commercially attractive?

The strongest package would combine a protected ready-to-administer presentation with validated stability, low waste, hospital workflow savings, and evidence supporting formulary adoption against low-cost generic opioids.

References

  1. U.S. Food and Drug Administration. (2020). OLINVYK (oliceridine) injection, prescribing information.
  2. U.S. Food and Drug Administration. (2020, August 7). FDA approves new opioid for acute pain in adults. https://www.fda.gov/news-events/press-announcements/fda-approves-new-opioid-acute-pain-adults
  3. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugsatfda
  4. Trevena, Inc. (2023). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.